Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results, Beats Estimates By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million.

Arbutus Biopharma Stock Up 5.0 %

Arbutus Biopharma stock traded up $0.17 during mid-day trading on Friday, reaching $3.44. The company had a trading volume of 549,396 shares, compared to its average volume of 854,479. The company has a 50 day moving average of $3.33 and a 200-day moving average of $3.58. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.72. The firm has a market cap of $650.91 million, a price-to-earnings ratio of -7.99 and a beta of 1.93.

Analyst Upgrades and Downgrades

ABUS has been the subject of a number of analyst reports. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. Chardan Capital restated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Arbutus Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.